Two Healthcare Tech Firms Establish New Field Of Data Economics Using Blockchain

Published at: May 16, 2018

Nebula Genomics and Longenisis, two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data, according to an announcement May 15. According to the release, they also aim to establish a new research field of “life data economics.”

Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical data. Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data.

The companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. In order to automate data acquisition, the project will utilize smart contracts. Professor George Church, co-founder of Nebula Genomics said:

"By allowing individuals and large data providers such as biobanks to maintain ownership of their genomic data on our platform and profit from it, Nebula Genomics seeks to incentivize generation of genomic data. In doing so, we will gather the data on a single network where it can be conveniently and securely accessed by researchers. In other words, we will make a marketplace that will create an equitable and efficient economy for genomic data."

Longenesis is developing a blockchain-based platform to store and exchange health-related data like lab test results. “Longenesis has built a similar platform that instead focuses on longitudinal health data, so our platforms complement one another very well," said Church.

Nebula Genomics and Longenesis say that their work will establish two new fields. The first, “microdataeconomics,” is “the study of the value of life data that is used for drug discovery such as proteomics or data regarding the structure and activity of specific molecules, both in vitro and in vivo.” The second, “macrodataeconomics,” is “ the study of the value of life data that is used to determine human health such as electronic health records and genomics.”

Earlier this month, a US-based life science research marketplace Scientist.com revealed a new blockchain platform called DataSmart. The blockchain-powered platform is reportedly designed to track and protect pharmaceutical data.

In April, US healthcare giant UnitedHealth Group announced a blockchain deployment to keep records up to date. The initiative aims to examine “how  sharing data across health care organizations on blockchain technology can improve data accuracy, streamline administration and improve access to care.”

Tags
Related Posts
$1B science fund seeks blockchain projects to expand human lifespan
Scientists are continuously pursuing ways to lengthen the human lifespan, and blockchain might have been a missing part of the puzzle. The Longevity Science Foundation, a Swiss entity launched by a consortium of biotech founders, clinicians and leading longevity research institutions, aims to spend more than $1 billion over the next 10 years to find tech-based means to achieve a 120-year human lifespan. The foundation seeks to fund research, institutions and projects that use blockchain and other next-gen technologies to find new horizons in four critical areas of the field; namely, therapeutics, personalized medicine, artificial intelligence (AI) and predictive diagnostics. …
Adoption / Sept. 30, 2021
Blockchain Genomics Firm, Merck’s EMD Serono Sign Anonymized Data Sharing Agreement
Blockchain firm Nebula Genomics has announced a collaboration with EMD Serono, the North American biopharmaceutical business of Merck KGaA — the world’s oldest operating pharmaceutical firm. The news was announced in a press release shared with Cointelegraph on June 11. As previously reported, Nebula is a blockchain-powered platform for genome-sequencing data, co-founded in 2017 by renowned geneticist Professor George Church and his Harvard colleagues Dennis Grishin and Kamal Obbad. The platform leverages blockchain technology in a bid to incentivize genomic data generation and sharing, and to lower the costs of genome-sequencing while preserving privacy and individuals’ control over their unique …
Adoption / June 11, 2019
Life’s Code: Blockchain and the Future of Genomics
In an era of hotly contested debates surrounding data ownership, privacy and monetization, one particular piece of data could be said to be the most personal of all: the human genome. While we are 99.9 percent identical in our genetic makeup across the species, the remaining 0.1 percent contains unique variations in code that are thought to influence our predisposition toward certain diseases and even our temperamental biases — a blueprint for how susceptible we are to everything from heart disease and Alzheimer’s to jealousy, recklessness and anxiety. 2018 offered ample examples of how bad actors can wreak havoc with …
Adoption / Sept. 3, 2018
Blockchain meets activity tracking: Project rewards healthy habits with tokens
Blockchain use cases continue to grow as the world learns about the benefits that it brings. Apart from bringing financial innovations like the ability to do peer-to-peer transactions, blockchain now makes its way to the health industry. Health specialists created a method to track and store health data using blockchain technology. Rosanne Warmerdam, the CEO of Health Blocks, told Cointelegraph that her team had developed a way for users to generate and store patients’ health data without sacrificing their privacy and security. “We wanted to start with giving users ownership and control over their health data,” said Warmerdam. By building …
Adoption / Jan. 21, 2022
Decentralization is helping to shape the course of scientific research and business
New technologies may have rapid, dramatic effects on society, but they may also spread slowly and subtly. Blockchain-powered decentralized science (DeSci) is taking off after some years of gestation. Its impact is being felt not only in the rarified confines of high-tech labs but more broadly in the business world as well. Psychedelics and longevity Paul Kohlhaas, co-founder and CEO of Molecule — a platform for biotech decentralized autonomous organizations (DAOs) founded in 2019 — spoke about pharmaceutical research and its funding on the Zima Red podcast in April. “We believe it could be way cheaper, if it was coordinated …
Decentralization / May 10, 2022